Depressive Symptoms and Risk of Acute Stroke INTERSTROKE Case-Control Study

dc.authorid0000-0002-7347-7761
dc.authorid0000-0002-6044-7328
dc.authorid0000-0001-5446-4175
dc.authorid0000-0001-5011-9008
dc.authorid0000-0001-9017-6103
dc.authorid0000-0002-5880-6352
dc.authorid0000-0002-6396-5913
dc.contributor.authorMurphy, Robert
dc.contributor.authorReddin, Catriona
dc.contributor.authorRosengren, Annika
dc.contributor.authorJudge, Conor J.
dc.contributor.authorHankey, Graeme
dc.contributor.authorFerguson, John
dc.contributor.authorAlvarez-Iglesias, Alberto
dc.date.accessioned2025-05-10T19:34:31Z
dc.date.issued2023
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground and Objectives Depression has been reported to be a risk factor of acute stroke, based largely on studies in high income countries. In the INTERSTROKE study, we explored the contribution of depressive symptoms to acute stroke risk and 1-month outcome across regions of the world, within subpopulations and by stroke type. Methods The INTERSTROKE is an international case-control study of risk factors of first acute stroke, conducted in 32 countries. Cases were patients with CT- or MRI-confirmed incident acute hospitalized stroke, and controls were matched for age, sex, and within sites. Standardized questions asked about self-reported depressive symptoms during the previous 12 months and the use of prescribed antidepressant medications were recorded. Multivariable conditional logistic regression was used to determine the association of prestroke depressive symptoms with acute stroke risk. Adjusted ordinal logistic regression was used to explore the association of prestroke depressive symptoms with poststroke functional outcome, measured with the modified Rankin scale at 1 month after stroke. Results Of 26,877 participants, 40.4% were women, and the mean age was 61.7 +/- 13.4 years. The prevalence of depressive symptoms within the last 12 months was higher in cases compared with that in controls (18.3% vs 14.1%, p < 0.001) and differed by region (p interaction <0.001), with lowest prevalence in China (6.9% in controls) and highest in South America (32.2% of controls). In multivariable analyses, prestroke depressive symptoms were associated with greater odds of acute stroke (odds ratio [OR] 1.46, 95% CI 1.34-1.58), which was significant for both intracerebral hemorrhage (OR 1.56, 95% CI 1.28-1.91) and ischemic stroke (OR 1.44, 95% CI 1.31-1.58). A larger magnitude of association with stroke was seen in patients with a greater burden of depressive symptoms. While preadmission depressive symptoms were not associated with a greater odds of worse baseline stroke severity (OR 1.02, 95% CI 0.94-1.10), they were associated with a greater odds of poor functional outcome at 1 month after acute stroke (OR 1.09, 95% CI 1.01-1.19). Discussion In this global study, we recorded that depressive symptoms are an important risk factor of acute stroke, including both ischemic and hemorrhagic stroke. Preadmission depressive symptoms were associated with poorer functional outcome, but not baseline stroke severity, suggesting an adverse role of depressive symptoms in poststroke recovery.
dc.description.sponsorshipCanadian Institutes of Health Research; Heart and Stroke Foundation of Canada; Canadian Stroke Network; Swedish Research Council; Swedish Heart and Lung Foundation; AFA insurance; Health amp; Medical Care Committee of the Regional Executive Board; Region Vastra Goetaland; Astra Zeneca; Boehringer Ingelheim (Canada); Pfizer (Canada); MERCK, Sharp and Dohme; Chest, and Heart and Stroke, Scotland; UK Stroke Association; Irish Clinical Academic Training (ICAT) Program; Wellcome Trust; Health Research Board [203930/B/16/Z]; Health Service Executive, National Doctors Training and Planning; Health and Social Care, Research and Development Division, Northern Ireland; European Research Council (COSIP grant) [640580]; European Research Council (ERC) [640580] Funding Source: European Research Council (ERC)
dc.description.sponsorship& nbsp;The INTERSTROKE study was funded by the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Swedish Research Council, Swedish Heart and Lung Foundation, AFA insurance, and Health & Medical Care Committee of the Regional Executive Board, Region Vastra Goetaland, and through unrestricted grants from several pharmaceutical companies with major contributions from Astra Zeneca, Boehringer Ingelheim (Canada), Pfizer (Canada), MERCK, Sharp and Dohme, Swedish Heart and Lung Foundation, Chest, and Heart and Stroke, Scotland, and UK Stroke Association. C. Judge was supported by the Irish Clinical Academic Training (ICAT) Program, the Wellcome Trust and the Health Research Board (grant number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning, and the Health and Social Care, Research and Development Division, Northern Ireland. M. O'Donnell was supported by the European Research Council (COSIP grant, 640580).
dc.identifier.doi10.1212/WNL.0000000000207093
dc.identifier.endpageE1798
dc.identifier.issn0028-3878
dc.identifier.issn1526-632X
dc.identifier.issue17
dc.identifier.pmid36889922
dc.identifier.scopus2-s2.0-85153803352
dc.identifier.scopusqualityQ1
dc.identifier.startpageE1787
dc.identifier.urihttps://doi.org/10.1212/WNL.0000000000207093
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8556
dc.identifier.volume100
dc.identifier.wosWOS:001019601700018
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofNeurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectMyocardial-Infarction
dc.subjectCountries
dc.subjectMetaanalysis
dc.subjectMortality
dc.subjectDisease
dc.subjectPsychotherapy
dc.subjectPrevalence
dc.subjectDisability
dc.subjectSeverity
dc.titleDepressive Symptoms and Risk of Acute Stroke INTERSTROKE Case-Control Study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
8556.pdf
Boyut:
498.16 KB
Biçim:
Adobe Portable Document Format